23andMe sells gene-testing business to DNA drug maker Regeneron
Los Angeles TimesMonday, May 19, 2025 at 1:33:09 PM
** 23andMe, the once-popular genetic-testing company that recently filed for bankruptcy, has struck a deal to sell its massive DNA database—previously holding info from 15 million customers—to biotech giant Regeneron for $256 million. Essentially, your spit kit data is changing hands.
What This Means: ** This isn’t just a corporate fire sale—it’s a big shift in who controls a treasure trove of genetic data. Regeneron, which develops drugs using genetic insights, could mine this info for future treatments. But it also raises questions: What happens to privacy promises made to 23andMe customers? And will this deal set a precedent for other struggling health-tech firms? Either way, your DNA might end up doing more than just tracing your ancestry.
— Curated via WP Now’s AI editorial system
